Sam Slutsky
Stock Analyst at LifeSci Capital
(4.98)
# 65
Out of 5,133 analysts
688
Total ratings
49.6%
Success rate
44.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sam Slutsky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVBP ArriVent BioPharma | Reiterated: Buy | $43 → $15 | $13.01 | +15.30% | 29 | Oct 6, 2026 | |
| CLDX Celldex Therapeutics | Reiterated: Buy | $64 | $28.83 | +121.99% | 46 | Oct 3, 2026 | |
| DBVT DBV Technologies | Reiterated: Buy | $45 | $11.02 | +308.53% | 14 | Sep 30, 2026 | |
| IRLA IRulya Therapeutics | Reiterated: Buy | $98 | $39.80 | +146.23% | 1 | Sep 30, 2026 | |
| TSX: EPRX Eupraxia Pharmaceuticals Inc. | Reiterated: Buy | $22.83 | $11.65 | +96.00% | 12 | Sep 30, 2026 | |
| OBX Obsidian Therapeutics | Reiterated: Buy | $43 | $12.56 | +242.36% | 2 | Sep 29, 2026 | |
| IMVT Immunovant | Reiterated: Buy | $53 | $34.18 | +55.06% | 74 | Sep 26, 2026 | |
| PYXS Pyxis Oncology | Reiterated: Buy | $8 | $1.58 | +406.33% | 25 | Sep 26, 2026 | |
| ORKA Oruka Therapeutics | Reiterated: Buy | $175 | $105.35 | +66.11% | 25 | Sep 23, 2026 | |
| ABVX ABIVAX Société Anonyme | Reiterated: Buy | $170 → $168 | $87.58 | +91.82% | 36 | Sep 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $16 | $7.56 | +111.64% | 46 | Sep 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $45 | $21.60 | +108.33% | 9 | Sep 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $55 | $28.56 | +92.58% | 52 | Sep 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $56 | $7.52 | +644.68% | 7 | Sep 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $116 | $104.00 | +11.54% | 59 | Sep 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $45 | $15.13 | +197.42% | 2 | Sep 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.1606 | - | 23 | Sep 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $60 → $70 | $48.80 | +43.44% | 38 | Aug 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $108 | $74.40 | +45.16% | 34 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $1.04 | - | 29 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $1.17 | +327.35% | 33 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $16 | $2.63 | +508.37% | 14 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $225 → $236 | $152.48 | +54.77% | 25 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $4.31 | n/a | 23 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | $33.21 → $20.41 | $2.07 | n/a | 30 | Apr 18, 2023 |
ArriVent BioPharma
Oct 6, 2026
Reiterated: Buy
Price Target: $43 → $15
Current: $13.01
Upside: +15.30%
Celldex Therapeutics
Oct 3, 2026
Reiterated: Buy
Price Target: $64
Current: $28.83
Upside: +121.99%
DBV Technologies
Sep 30, 2026
Reiterated: Buy
Price Target: $45
Current: $11.02
Upside: +308.53%
IRulya Therapeutics
Sep 30, 2026
Reiterated: Buy
Price Target: $98
Current: $39.80
Upside: +146.23%
Eupraxia Pharmaceuticals Inc.
Sep 30, 2026
Reiterated: Buy
Price Target: $22.83
Current: $11.65
Upside: +96.00%
Obsidian Therapeutics
Sep 29, 2026
Reiterated: Buy
Price Target: $43
Current: $12.56
Upside: +242.36%
Immunovant
Sep 26, 2026
Reiterated: Buy
Price Target: $53
Current: $34.18
Upside: +55.06%
Pyxis Oncology
Sep 26, 2026
Reiterated: Buy
Price Target: $8
Current: $1.58
Upside: +406.33%
Oruka Therapeutics
Sep 23, 2026
Reiterated: Buy
Price Target: $175
Current: $105.35
Upside: +66.11%
ABIVAX Société Anonyme
Sep 22, 2026
Reiterated: Buy
Price Target: $170 → $168
Current: $87.58
Upside: +91.82%
Sep 19, 2026
Reiterated: Buy
Price Target: $16
Current: $7.56
Upside: +111.64%
Sep 18, 2026
Reiterated: Buy
Price Target: $45
Current: $21.60
Upside: +108.33%
Sep 15, 2026
Reiterated: Buy
Price Target: $55
Current: $28.56
Upside: +92.58%
Sep 11, 2026
Reiterated: Buy
Price Target: $56
Current: $7.52
Upside: +644.68%
Sep 8, 2026
Reiterated: Buy
Price Target: $116
Current: $104.00
Upside: +11.54%
Sep 5, 2026
Reiterated: Buy
Price Target: $45
Current: $15.13
Upside: +197.42%
Sep 2, 2026
Downgraded: Hold
Price Target: n/a
Current: $0.1606
Upside: -
Aug 8, 2026
Rated: Buy
Price Target: $60 → $70
Current: $48.80
Upside: +43.44%
Aug 7, 2026
Reiterated: Buy
Price Target: $108
Current: $74.40
Upside: +45.16%
Aug 6, 2026
Reiterated: Hold
Price Target: n/a
Current: $1.04
Upside: -
Aug 6, 2026
Reiterated: Buy
Price Target: $5
Current: $1.17
Upside: +327.35%
Aug 5, 2026
Reiterated: Buy
Price Target: $16
Current: $2.63
Upside: +508.37%
Aug 5, 2026
Reiterated: Buy
Price Target: $225 → $236
Current: $152.48
Upside: +54.77%
Aug 9, 2023
Rated: Hold
Price Target: n/a
Current: $4.31
Upside: n/a
Apr 18, 2023
Upgraded: Hold
Price Target: $33.21 → $20.41
Current: $2.07
Upside: n/a